دورية أكاديمية
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation.
| العنوان: | Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation. |
|---|---|
| المؤلفون: | Antonarelli G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, 20139 Milan, Italy.; Department of Oncology and Hemato-Oncology (DIPO), University of Milan, 20122 Milan, Italy., Pieri V; Neural Stem Cell Biology Unit, Division of Neuroscience, IRCCS San Raffaele Hospital, 20132 Milan, Italy.; Vita-Salute San Raffaele University, 20132 Milan, Italy., Porta FM; Division of Pathology, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy.; School of Pathology, University of Milan, 20122 Milan, Italy., Fusco N; Department of Oncology and Hemato-Oncology (DIPO), University of Milan, 20122 Milan, Italy.; Division of Pathology, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy., Finocchiaro G; Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, 20139 Milan, Italy.; Department of Oncology and Hemato-Oncology (DIPO), University of Milan, 20122 Milan, Italy., Criscitiello C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, 20139 Milan, Italy.; Department of Oncology and Hemato-Oncology (DIPO), University of Milan, 20122 Milan, Italy. |
| المصدر: | Cells [Cells] 2023 Mar 08; Vol. 12 (6). Date of Electronic Publication: 2023 Mar 08. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy, Humans ; Female ; Glycosylation ; Protein Processing, Post-Translational ; Biomarkers |
| مستخلص: | Various tumors rely on post-translational modifications (PTMs) to promote invasiveness and angiogenesis and to reprogram cellular energetics to abate anti-cancer immunity. Among PTMs, fucosylation is a particular type of glycosylation that has been linked to different aspects of immune and hormonal physiological functions as well as hijacked by many types of tumors. Multiple tumors, including breast cancer, have been linked to dismal prognoses and increased metastatic potential due to fucosylation of the glycan core, namely core-fucosylation. Pre-clinical studies have examined the molecular mechanisms regulating core-fucosylation in breast cancer models, its negative prognostic value across multiple disease stages, and the activity of in vivo pharmacological inhibition, instructing combinatorial therapies and translation into clinical practice. Throughout this review, we describe the role of fucosylation in solid tumors, with a particular focus on breast cancer, as well as physiologic conditions on the immune system and hormones, providing a view into its potential as a biomarker for predicating or predicting cancer outcomes, as well as a potential clinical actionability as a biomarker. |
| References: | Nat Commun. 2018 Aug 23;9(1):3380. (PMID: 30140003) J Biochem. 2019 Mar 1;165(3):227-237. (PMID: 30445455) Mol Cell Proteomics. 2011 Oct;10(10):M111.010090. (PMID: 21653738) Front Oncol. 2018 Dec 07;8:565. (PMID: 30619732) Blood. 2008 Jul 15;112(2):308-19. (PMID: 18359890) J Clin Invest. 2013 May;123(5):2183-92. (PMID: 23563315) PLoS Pathog. 2016 Mar 16;12(3):e1005456. (PMID: 26982805) PLoS One. 2013 Oct 09;8(10):e76540. (PMID: 24130780) Expert Rev Proteomics. 2019 Aug;16(8):665-680. (PMID: 31314995) Nature. 2007 Oct 11;449(7163):682-8. (PMID: 17898713) Br J Cancer. 2019 Jan;120(1):45-53. (PMID: 30413828) Cell Commun Signal. 2020 Feb 28;18(1):33. (PMID: 32111215) Nat Chem Biol. 2012 Jul;8(7):661-8. (PMID: 22683610) Histol Histopathol. 2016 May;31(5):547-55. (PMID: 26596733) Clin Cancer Res. 2019 Jul 1;25(13):3996-4013. (PMID: 30867218) Antibodies (Basel). 2019 Jan 10;8(1):. (PMID: 31544815) JAMA Oncol. 2022 Apr 01;8(4):629-635. (PMID: 35024766) Arthritis Rheumatol. 2014 Sep;66(9):2368-79. (PMID: 24838610) Sci Transl Med. 2021 Jun 2;13(596):. (PMID: 33979301) Oncoimmunology. 2019 Jun 24;8(9):e1629257. (PMID: 31428526) Breast Cancer Res. 2017 Oct 5;19(1):111. (PMID: 28982386) Mol Cancer. 2014 Jun 04;13:142. (PMID: 24897960) Cancer Discov. 2020 Aug;10(8):1194-1209. (PMID: 32414908) Sci Immunol. 2021 Mar 26;6(57):. (PMID: 33771887) Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74. (PMID: 21768335) Oncol Lett. 2018 Aug;16(2):2097-2104. (PMID: 30008906) Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5404-9. (PMID: 23493549) Cell Rep. 2016 Aug 2;16(5):1259-1272. (PMID: 27452466) Immunity. 2015 Mar 17;42(3):419-30. (PMID: 25786174) Nature. 2008 Oct 23;455(7216):E8-9; author reply E9. (PMID: 18948893) Clin Exp Pharmacol Physiol. 2019 Oct;46(10):955-967. (PMID: 31381176) J Biol Chem. 2012 Jan 20;287(4):2500-8. (PMID: 22084235) JCI Insight. 2017 Feb 23;2(4):e89703. (PMID: 28239652) J Cancer Res Clin Oncol. 2018 Nov;144(11):2109-2115. (PMID: 30101373) Sci Rep. 2014 Sep 01;4:6145. (PMID: 25174450) Cell Chem Biol. 2017 Dec 21;24(12):1467-1478.e5. (PMID: 29033318) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) Front Oncol. 2020 Aug 18;10:1622. (PMID: 33014816) Nat Commun. 2021 May 11;12(1):2672. (PMID: 33976130) Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. (PMID: 28117416) Annu Rev Pathol. 2015;10:473-510. (PMID: 25621663) Genes Cells. 2011 Nov;16(11):1071-80. (PMID: 22023369) Int J Mass Spectrom. 2019 Mar;437:69-76. (PMID: 31031563) Trends Immunol. 2015 Apr;36(4):229-39. (PMID: 25770924) Cancer Res. 2023 Jan 18;83(2):195-218. (PMID: 36409826) World J Gastroenterol. 2019 Jun 21;25(23):2947-2960. (PMID: 31249452) Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):630-5. (PMID: 23267084) Nat Commun. 2014 Oct 03;5:5074. (PMID: 25278262) Glycobiology. 2000 Jun;10(6):637-43. (PMID: 10814706) PLoS One. 2014 Sep 03;9(9):e106255. (PMID: 25184632) Cell Rep. 2017 Aug 1;20(5):1017-1028. (PMID: 28768188) Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1539-44. (PMID: 18227520) Cancers (Basel). 2019 Aug 24;11(9):. (PMID: 31450600) Front Oncol. 2018 Feb 23;8:39. (PMID: 29527514) PLoS One. 2015 Feb 23;10(2):e0117772. (PMID: 25706118) Sci Transl Med. 2022 Nov 2;14(669):eabj1270. (PMID: 36322632) J Cell Physiol. 2015 Feb;230(2):473-81. (PMID: 25078559) Lancet. 2021 May 8;397(10286):1750-1769. (PMID: 33812473) Front Immunol. 2018 Nov 27;9:2754. (PMID: 30538706) Glycobiology. 2017 Jul 1;27(7):601-618. (PMID: 28430973) J Biochem. 2008 Jun;143(6):725-9. (PMID: 18218651) Sci Rep. 2017 Sep 14;7(1):11563. (PMID: 28912543) Int J Mol Sci. 2019 May 23;20(10):. (PMID: 31126011) Cancer Immunol Res. 2020 Oct;8(10):1262-1272. (PMID: 32819969) J Transl Med. 2021 Nov 3;19(1):455. (PMID: 34732216) Cancer Cell. 2017 Jun 12;31(6):804-819.e7. (PMID: 28609658) Science. 2021 Jun 4;372(6546):1102-1105. (PMID: 34083490) Clin Chim Acta. 2018 Dec;487:84-89. (PMID: 30189188) Lancet. 2018 Mar 17;391(10125):1023-1075. (PMID: 29395269) Mol Cancer. 2020 Sep 24;19(1):145. (PMID: 32972405) Cancer Sci. 2021 Aug;112(8):3190-3204. (PMID: 34036684) Sci Rep. 2015 Feb 05;5:8264. (PMID: 25652335) Glycoconj J. 2020 Aug;37(4):435-444. (PMID: 32367479) Cell. 2011 Aug 5;146(3):353-8. (PMID: 21802130) Blood. 2011 May 26;117(21):5652-62. (PMID: 21464368) Science. 2021 Feb 26;371(6532):. (PMID: 33361116) Prostate Cancer Prostatic Dis. 2018 Apr;21(1):137-146. (PMID: 29339807) Biomolecules. 2012 Oct 11;2(4):435-66. (PMID: 24970145) Int J Mol Sci. 2022 Oct 10;23(19):. (PMID: 36233358) J Immunol. 2015 Mar 15;194(6):2596-606. (PMID: 25694612) Biomolecules. 2012 Jan 30;2(1):34-45. (PMID: 24970126) Nat Rev Cancer. 2015 Sep;15(9):540-55. (PMID: 26289314) Cancers (Basel). 2019 Oct 01;11(10):. (PMID: 31581535) Oncologist. 2021 Nov;26(11):925-e1918. (PMID: 34288257) MAbs. 2017 Jan;9(1):114-126. (PMID: 27786612) J Gastroenterol Hepatol. 2011 Jul;26(7):1195-200. (PMID: 21410750) iScience. 2022 Feb 10;25(3):103897. (PMID: 35243255) Glycobiology. 2004 Jan;14(1):13-25. (PMID: 14514715) Surg Today. 2020 Jul;50(7):767-777. (PMID: 31950256) Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204) Expert Rev Proteomics. 2020 Jan;17(1):11-25. (PMID: 31914820) Proteomics Clin Appl. 2019 Jan;13(1):e1800014. (PMID: 30592377) Sci Rep. 2017 Oct 23;7(1):13780. (PMID: 29062024) Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3485-3490. (PMID: 28289219) Mol Cancer Ther. 2020 May;19(5):1102-1109. (PMID: 32165557) Cancers (Basel). 2022 Aug 31;14(17):. (PMID: 36077781) Curr Opin Struct Biol. 2018 Aug;51:141-148. (PMID: 29753204) JCI Insight. 2021 Dec 22;6(24):. (PMID: 34752419) Blood. 2021 Oct 21;138(16):1481-1489. (PMID: 34315173) Carbohydr Res. 2018 May 23;465:4-9. (PMID: 29874559) Clin Cancer Res. 2019 Apr 15;25(8):2610-2620. (PMID: 30647079) J Exp Clin Cancer Res. 2019 May 14;38(1):195. (PMID: 31088482) Immunol Res. 2023 Feb;71(1):92-104. (PMID: 36197587) J Pathol. 2020 Apr;250(5):573-592. (PMID: 32086811) |
| فهرسة مساهمة: | Keywords: biomarkers; breast cancer; fucosylation; glycosylation; metastasis |
| المشرفين على المادة: | 0 (Biomarkers) |
| تواريخ الأحداث: | Date Created: 20230329 Date Completed: 20230330 Latest Revision: 20230426 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10047715 |
| DOI: | 10.3390/cells12060840 |
| PMID: | 36980181 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2073-4409 |
|---|---|
| DOI: | 10.3390/cells12060840 |